Mark J. Gergen has joined San Diego-based Poseida Therapeutics as chief business officer and chief financial officer, bringing 25 years of life sciences experience.
Most recently he was the senior vice president and chief operating officer of Halozyme Therapeutics, and prior to that the vice president of Mirati Therapetucs where he had responsibility for all business operations, including functions of both COO and CFO.
From 2005 until the sale of Amylin Pharmaceuticals to Bristol-Myers Squibb in August 2012, he was the senior vice president of corporate development.
Poseida is translating gene engineering technologies into cell therapies. It was spun out from Lexington, Ky.-based Transposagen Biopharmaceuticals.
Gergen holds a J.D. from the University of Minnesota Law School and a B.A. in Business Administration from Minot State University.